.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Covington
McKinsey
Accenture
US Department of Justice
Boehringer Ingelheim
UBS
Farmers Insurance
Chinese Patent Office
Cipla

Generated: December 15, 2017

DrugPatentWatch Database Preview

NEXTERONE Drug Profile

« Back to Dashboard

Which patents cover Nexterone, and when can generic versions of Nexterone launch?

Nexterone is a drug marketed by Baxter Hlthcare and is included in one NDA. There are two patents protecting this drug.

This drug has forty-four patent family members in twenty countries.

The generic ingredient in NEXTERONE is amiodarone hydrochloride. There are fifteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the amiodarone hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Baxter HlthcareNEXTERONEamiodarone hydrochlorideINJECTABLE;INJECTION022325-001Dec 24, 2008APRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Baxter HlthcareNEXTERONEamiodarone hydrochlorideINJECTABLE;INJECTION022325-002Nov 16, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Baxter HlthcareNEXTERONEamiodarone hydrochlorideINJECTABLE;INJECTION022325-001Dec 24, 2008APRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Baxter HlthcareNEXTERONEamiodarone hydrochlorideINJECTABLE;INJECTION022325-002Nov 16, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Baxter HlthcareNEXTERONEamiodarone hydrochlorideINJECTABLE;INJECTION022325-003Nov 16, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Baxter HlthcareNEXTERONEamiodarone hydrochlorideINJECTABLE;INJECTION022325-003Nov 16, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NEXTERONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter HlthcareNEXTERONEamiodarone hydrochlorideINJECTABLE;INJECTION022325-001Dec 24, 2008► Subscribe► Subscribe
Baxter HlthcareNEXTERONEamiodarone hydrochlorideINJECTABLE;INJECTION022325-001Dec 24, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NEXTERONE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,410,077Sulfoalkyl ether cyclodextrin compositions► Subscribe
9,750,822Sulfoalkyl ether cyclodextrin compositions► Subscribe
9,200,088Sulfoalkyl ether cyclodextrin compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NEXTERONE

Country Document Number Estimated Expiration
European Patent Office2402008► Subscribe
European Patent Office1501496► Subscribe
Spain2567716► Subscribe
Canada2702603► Subscribe
Portugal1501496► Subscribe
Hong Kong1219883► Subscribe
Israel165022► Subscribe
MexicoPA04010925► Subscribe
Austria535239► Subscribe
China101959508► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Accenture
Chinese Patent Office
Novartis
US Army
QuintilesIMS
Cantor Fitzgerald
Federal Trade Commission
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot